Personalized Neoantigen Cancer Vaccine – Talk Bio

Actionable Insights Powered by AI

Gritstone Cancer Vaccine Trial Misses Primary Endpoint, Stock Plummets

1 year ago talkbio0Tagged Circulating, Circulating Tumor DNA, Colorectal Carcinoma, Gritstone, Personalized Neoantigen Cancer Vaccine, Phase 2 Clinical Trials, Progression-Free Survival, Stock Market Reaction

Gritstone, Personalized Neoantigen Cancer Vaccine, Colorectal Cancer, Phase 2 Study Failure, Circulating Tumor DNA (ctDNA), Progression-Free Survival (PFS), Stock Market Reaction